Creating successful businesses through venture capital partnerships
Amir Nashat, Managing Partner, Polaris Partners
Come learn about a new model for venture capital that involves seeking deeper, long-term relationships with entrepreneurs. This means not just seeding companies, but often working with academics and entrepreneurs at the ideation stage, months or years before a company is formed. We are committed, long-term partners, supporting these companies through their growth. We also invest at later rounds and provide growth equity to revenue generating, high-growth businesses.
Amir Nashat currently represents Polaris Partners as Director of AgBiome, aTyr Pharmaceuticals, BIND Therapeutics, Fate Therapeutics, Promedior Pharmaceuticals, Scholar Rock, and Selecta Biosciences. Additionally, Amir has served as a Director at Adnexus Therapeutics (acquired by Bristol Myers Squibb), Athenix Corporation (acquired by Bayer), Avila Therapeutics (acquired by Celgene), Living Proof, Pervasis Therapeutics (acquired by Shire Pharmaceuticals), and Sun Catalytix (acquired by Lockheed Martin). In addition to his role as an investor, Amir has also served as the initial CEO of Living Proof and Sun Catalytix Corporation. He has been named to the Forbes Midas list of Top 100 Venture Capitalists.
Time & Location: 123 Snell Library, 4:30pm, February 20